MFMir Sohail Fazeli

Mir Sohail Fazeli

*This is an algorithmically generated author record based on publicly available information.

Mir Sohail Fazeli has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automating Screening of Titles and Abstracts in Systematic Reviews: An Assessment of GPT-4o mini

    by Mir Sohail Fazeli, Ellen Kasireddy, Mir-Masoud Pourrahmat, Cuthbert Chow, Jean-Paul Collet

    Background: Systematic literature reviews (SLRs) are essential in medical research, but are often time-consuming and costly, necessitating more efficient methods while maintaining accuracy. Objective: This study assessed the performance of a GPT-4o mini large language model (LLM) in automating the first phase of study selection based on titles and abstracts in systematic reviews. Specifically, we evaluated whether the model improved efficiency without compromising on quality. Methods: Structured prompts were created for a GPT-4o mini LLM to facilitate title and abstract screening. The model’s performance was evaluated against expert human reviewers across five systematic reviews on inclusion rates, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value. Results: The model screened a total of 15,605 records. It included a higher percentage of studies than human screeners, with 3.5% (n=549/15,605) true positives and 14.2% (n=2,218/15,605) false positives. The model achieved an overall accuracy of 85.1%, with a sensitivity of 83.2% and specificity of 85.2%. The positive predictive value was 19.8%, while the negative predictive value was 99.1%. The model was able to screen 1,000 titles and abstracts in 40 minutes, compared to 16 hours required by a human reviewer. Conclusion: This study demonstrated a strong performance and efficiency in the automation of title and abstract screening in SLRs using an advanced LLM. Further refinements could optimize the balance between sensitivity and specificity, supporting broader implementation in evidence synthesis. A hybrid AI-human approach is recommended to ensure accuracy, reduce reviewer burden, and maintain the methodological rigor required for high-quality SLRs.

  • Open Access

    Evaluating the Performance of Claude 3.7 Sonnet in Data Extraction Automation for Systematic Literature Reviews

    by Ellen Kasireddy, Cuthbert Chow, Jun Collet, Mir-Masoud Pourrahmat, Mir Sohail Fazeli


  • Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis

    by Akihiko Asahina, Mir Sohail Fazeli, Robyn Kendall, Gopika Balasubramanian, Paul Serafini, Asif Shaikh, Ranga Gogineni, Jianzhong Zhang

    Many biologic therapies are available for moderate‐to‐severe plaque psoriasis. A systematic literature review and network meta‐analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)‐23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate‐to‐severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid‐term (28 weeks) follow‐up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor‐alpha (TNFα), IL‐17, IL‐12/IL‐23, and other IL‐23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate‐to‐severe plaque psoriasis.


  • Open Access

    Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysis

    by Jagmeet P. Singh, Carina Blomström‐Lundqvist, Mintu P. Turakhia, A. John Camm, Mir Sohail Fazeli, Bahij Kreidieh, Christopher Crotty, Peter R. Kowey

    Background: There are limited comparative data on safety and efficacy within commonly used Vaughan‐Williams (VW) class III antiarrhythmic drugs (AADs) for maintenance of sinus rhythm in adults with atrial fibrillation (AF).Hypothesis: We hypothesized that dronedarone and sotalol, two commonly prescribed VW class III AADs with class II properties, have different safety and efficacy effects in patients with nonpermanent AF.Methods: A systematic literature review was conducted searching MEDLINE®, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to June 15, 2021 (NCT05279833). Clinical trials and observational studies that evaluated safety and efficacy of dronedarone or sotalol in adults with AF were included. Bayesian random‐effects network meta‐analysis (NMA) was used to quantify comparative safety and efficacy. Where feasible, we performed sensitivity analyses by including only randomized controlled trials (RCTs).Results: Of 3581 records identified through database searches, 37 unique studies (23 RCTs, 13 observational studies, and 1 nonrandomized trial) were included in the NMA. Dronedarone was associated with a statistically significantly lower risk of all‐cause death versus sotalol (hazard ratio [HR] = 0.38 [95% credible interval, CrI: 0.19, 0.74]). The association was numerically similar in the sensitivity analysis (HR = 0.46 [95% CrI: 0.21, 1.02]). AF recurrence and cardiovascular death results were not significantly different between dronedarone and sotalol in all‐studies and sensitivity analyses.Conclusion: The NMA findings indicate that, across all clinical trials and observational studies included, dronedarone compared with sotalol was associated with a lower risk of all‐cause death, but with no difference in AF recurrence.


  • Open Access

    Personality diversity in the workplace: A systematic literature review on introversion

    by Juliet Herbert, Leticia Ferri, Brenda Hernandez, Isaias Zamarripa, Kimberly Hofer, Mir Sohail Fazeli, Iryna Shnitsar, Kald Abdallah

    Up to half of the population have introverted personalities. Workplace diversity can lead to increased productivity, creativity and problem-solving. Understanding introversion in relation to workplace performance and creativity and how to encourage inclusion of introverts would benefit employers and employees. We describe the evidence defining and evaluating introversion, prevalence of introversion across groups, and strategies for promoting workplace inclusion of introverts. We searched MEDLINE®, Embase, and PsycINFO up to February 11, 2021. Of 2,724 records, 21 studies were included. Introversion definitions were generally negative and dated. Robust prevalence data were unavailable, and no studies aimed to test strategies for promoting workplace inclusion of introversion. Nevertheless, literature suggests that employees who identify with modern definitions of introversion may benefit from individualized workplace strategies such as flexible working environments, work/home-life boundaries, varied team composition, provision of social support, and relaxation training. Further empirical studies in the industrial setting with robust designs using modernized personality definitions are warranted to support the development of effective strategies to increase inclusion of different personalities in the workplace.


  • Open Access

    Digital Devices for Assessing Motor Functions in Mobility-Impaired and Healthy Populations: Systematic Literature Review

    by Christine C Guo, Patrizia Andrea Chiesa, Carl de Moor, Mir Sohail Fazeli, Thomas Schofield, Kimberly Hofer, Shibeshih Belachew, Alf Scotland

    Background: With the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor function outcomes. Objective: We aimed to describe the existing scientific literature on wearable and mobile technologies that are being used or tested for assessing motor functions in mobility-impaired and healthy adults and to evaluate the degree to which these devices provide clinically valid measures of motor function in these populations. Methods: A systematic literature review was conducted by searching Embase, MEDLINE, CENTRAL (January 1, 2015, to June 24, 2020), the United States and European Union clinical trial registries, and the United States Food and Drug Administration website using predefined study selection criteria. Study selection, data extraction, and quality assessment were performed by 2 independent reviewers. Results: A total of 91 publications representing 87 unique studies were included. The most represented clinical conditions were Parkinson disease (n=51 studies), followed by stroke (n=5), Huntington disease (n=5), and multiple sclerosis (n=2). A total of 42 motion-detecting devices were identified, and the majority (n=27, 64%) were created for the purpose of health care–related data collection, although approximately 25% were personal electronic devices (eg, smartphones and watches) and 11% were entertainment consoles (eg, Microsoft Kinect or Xbox and Nintendo Wii). The primary motion outcomes were related to gait (n=30), gross motor movements (n=25), and fine motor movements (n=23). As a group, sensor-derived motion data showed a mean sensitivity of 0.83 (SD 7.27), a mean specificity of 0.84 (SD 15.40), a mean accuracy of 0.90 (SD 5.87) in discriminating between diseased individuals and healthy controls, and a mean Pearson r validity coefficient of 0.52 (SD 0.22) relative to clinical measures. We did not find significant differences in the degree of validity between in-laboratory and at-home sensor-based assessments nor between device class (ie, health care–related device, personal electronic devices, and entertainment consoles). Conclusions: Sensor-derived motion data can be leveraged to classify and quantify disease status for a variety of neurological conditions. However, most of the recent research on digital clinical measures is derived from proof-of-concept studies with considerable variation in methodological approaches, and much of the reviewed literature has focused on clinical validation, with less than one-quarter of the studies performing analytical validation. Overall, future research is crucially needed to further consolidate that sensor-derived motion data may lead to the development of robust and transformative digital measurements intended to predict, diagnose, and quantify neurological disease state and its longitudinal change.


  • Open Access

    Digital Devices for Assessing Motor Functions in Mobility Impaired and Healthy Populations: A Systematic Literature Review (Preprint)

    by Christine C. Guo, Patrizia Andrea Chiesa, Carl de Moor, Mir Sohail Fazeli, Thomas Schofield, Kimberly Hofer, Shibeshih Belachew, Alf Scotland

    BACKGROUND With the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor function outcomes. OBJECTIVE We aimed to describe the existing scientific literature on wearable and mobile technologies that are being used or tested for assessing motor functions in mobility-impaired and healthy adults, and to evaluate the degree to which these devices provide clinically valid measures of motor function in these populations. METHODS A systematic literature review was conducted by searching Embase, MEDLINE®, CENTRAL (January 1, 2015 – June 24, 2020), the United States and European Union clinical trial registries, and the United States Food and Drug Administration website using predefined study selection criteria. Study selection, data extraction, and quality assessment were performed by two independent reviewers. RESULTS Ninety-one publications representing 87 unique studies were included. The most represented clinical conditions were Parkinson’s disease (k = 51 studies), followed by stroke (k = 5), Huntington’s disease (k = 5), and multiple sclerosis (k = 2). A total of 42 motion-detecting devices were identified, and the majority (k = 27; 64%) were created for the purpose of healthcare-related data collection, though approximately 25% were personal electronic devices (e.g., smartphones, watches) and 11% were entertainment consoles (e.g., Microsoft Kinect/Xbox™, Nintendo Wii™). The primary motion outcomes were related to gait (k = 30), gross motor movements (k = 25), and fine motor movements (k = 23). As a group, sensor-derived motion data showed a mean sensitivity of .83 (SD = 7.27), mean specificity of .84 (SD = 15.40), mean accuracy of .90 (SD = 5.87) in discriminating between diseased individuals and healthy controls, and mean Pearson’s r validity coefficient of .52 (SD = 0.22) relative to clinical measures. We did not find significant differences in the degree of validity between in-lab and at-home sensor-based assessments, nor between device class (i.e., healthcare-related device, personal electronic devices, entertainment consoles). CONCLUSIONS Sensor-derived motion data can be leveraged to classify and quantify disease status for a variety of neurological conditions. However, most of recent research on digital clinical measures is derived from proof-of-concept studies with considerable variation in methodological approaches, and much of the reviewed literature has focused on clinical validation, with less than a quarter of the studies performing analytical validation. Overall, future research is crucially needed to further consolidate that sensor-derived motion data may lead to the development of robust and transformative digital measurements intended to predict, diagnose, and quantify neurological disease state and its longitudinal change.

  • Open Access

    Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence

    by Mir Sohail Fazeli, Louis McIntyre, Yili Huang, Xavier Chevalier

    Knee osteoarthritis (KOA) is a debilitating disease characterized by chronic pain, stiffness, and decreased mobility. Intra-articular injectable therapies show good clinical efficacy in improving symptoms; however, these therapies and their comparators (intra-articular saline) have been associated with a large underlying placebo effect. We aimed to describe the existing evidence on the challenges, hypotheses, and potential solutions to mitigate the intra-articular placebo effect in clinical trials in KOA. A targeted literature review was conducted by searching Embase, MEDLINE®, and CENTRAL using predefined study selection criteria. All eligible studies identified were extracted for relevant data, and results were narratively summarized. Forty-three studies were included following screening. Challenges associated with the intra-articular placebo effect included its ability to mask the comparative efficacy of active treatments in trials ( n = 7 studies), long-lasting effects (up to 6 months; n = 3), and substantial variation of placebo effect sizes across populations ( n = 3). Hypotheses for the mechanism of the placebo effect included aspiration of synovial fluid during administration ( n = 6) and dilution of inflammatory mediators ( n = 2). Factors affecting the placebo effect size were more invasive routes of administration (e.g., injection versus oral; n = 4) and patient expectations ( n = 2). Proposed solutions included the suggestion for readers to weigh the relevance of clinical trial evidence against the presence of large underlying placebo effects ( n = 9), discontinuation of intra-articular saline as an appropriate placebo ( n = 5), and inclusion of ‘no treatment’ or sham injection as a control ( n = 4). The intra-articular placebo effect is a well-documented occurrence in KOA clinical trials, and it is suggested that it be accounted for when designing randomized controlled trials. Awareness and understanding of the intra-articular placebo effect in KOA are required for fair interpretation of clinical trial evidence.


  • Open Access

    A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies

    by Jose G. Montoya, Katherine Laessig, Mir Sohail Fazeli, Gaye Siliman, Sophie S. Yoon, Elizabeth Drake-Shanahan, Chengyue Zhu, Akbar Akbary, Rima McLeod

    Purpose: We aimed to investigate the effect of antepartum treatment with spiramycin with or without subsequent pyrimethamine–sulfonamide–folinic acid, compared to no treatment, on the rate of mother-to-child transmission (MTCT) of Toxoplasma gondii (T. gondii) and incidence/severity of sequelae in the offspring. Methods: Embase and PubMed were searched for literature on spiramycin in pregnant women suspected/diagnosed with T. gondii infection. Meta-analyses were performed using random-effects model. Results: Thirty-three studies (32 cohorts and 1 cross-sectional study), with a total of 15,406 mothers and 15,250 offspring, were pooled for analyses. The MTCT rate for all treated patients was significantly lower than the untreated [19.5% (95% CI 14–25.5%) versus 50.7% (95% CI 31.2–70%), p < 0.001]. The transmission rate in patients on spiramycin monotherapy was also significantly lower than untreated [17.6% (95% CI 9.9–26.8%) versus 50.7% (95% CI 31.2–70%), p < 0.001]. Conclusion: Results indicate significant reduction in MTCT rates following spiramycin treatment of suspected/diagnosed maternal T. gondii infection.


  • Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape

    by Mir Sohail Fazeli, Vadim Khaychuk, Keith Wittstock, Xue Han, Grace Crocket, Margaret Lin, Sarah L. Hill, Leticia Ferri

    Reviews; Authors: M.S. Fazeli, V. Khaychuk, K. Wittstock, X. Han, G. Crocket, M. Lin, S.L. Hill, L. Ferri